Improvement in β-cell function after diet-induced weight loss is associated with decrease in pancreatic polypeptide in subjects with type 2 diabetes

What Was Tested

The paper reports a study of Pancreatic Polypeptide in the context of pancreatitis (after the acute phase), published as a clinical trial.

The aim of their study was to evaluate the effect of a lifestyle intervention program on β-cell function and to explore the role of gastrointestinal peptides in subjects with T2D.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

Subjects with T2D (n=74) received 24 weeks of intervention: 12 weeks of slimming diet (-500 kcal/day) and the subsequent 12 weeks of diet were combined with aerobic exercise.

All subjects were examined at weeks 0, 12 and 24. β-cell function was assessed during standard meal tests.

How the Study Was Run

Insulin secretory rate (ISR) was calculated by C-peptide deconvolution, and β-cell function was quantified with a mathematical model.

Plasma concentrations of gastrointestinal peptides were measured in a fasting state and during hyperinsulinemia induced by hyperinsulinemic isoglycemic clamp.

What Was Measured

The subject headings attached to it are Body Mass Index, C-Peptide, Combined Modality Therapy, Diabetes Mellitus, Type 2, Diet, Reducing, Down-Regulation and Exercise.

What This Means in Plain Language

This is a clinical trial of Pancreatic Polypeptide in people with pancreatitis (after the acute phase).

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2012 (Journal of diabetes and its complications), a journal based in United States.

More context: the Pancreatic Polypeptide compound page, Pancreatitis (after the acute phase) research.